22978s22755
NM_001134373.2 NM_012229.4 XM_005269632.4 XM_005269633.4 XM_005269634.4 XM_005269635.4 XM_005269636.4 XM_005269637.4 XM_005269638.4 XM_005269639.4 XM_005269640.4 XM_005269641.4 XM_005269642.4 XM_005269643.4 XM_005269644.4 XM_005269645.4 XM_005269646.4 XM_006717721.3 XM_006717723.3 XM_011539537.2 XM_017015947.1 XM_017015948.1 XM_017015949.1 XM_017015950.1 XM_017015951.1 XM_017015952.1 XM_017015953.1 XM_017015954.1 XM_017015955.1 XM_017015956.1 XM_017015957.1 XM_017015958.1 XM_017015959.1 XM_017015960.1 XM_017015961.1 XM_017015962.1 XM_017015963.1 XM_017015964.1 XM_017015965.1 XM_017015966.1 XM_017015967.1 XM_017015968.1 XM_017015969.1 XM_017015970.1 XM_017015971.1 XM_017015972.1 XM_017015973.1 XM_017015974.1 XM_017015975.1 XM_017015976.1
9%(+/-2% mRNA remaining)(HeLa cell line) [TaqMan® Assay ID: Hs00366992_m1]
HeLa cells were reverse transfected with 5nM gene-specific Silencer® Select siRNA or 5nM Silencer® Select Negative Control #2 siRNA. 48 hours post-transfection, gene expression analysis was performed using the TaqMan® Gene Expression Cells-to-CT Kit and appropriate TaqMan® Gene Expression Assays. 18S rRNA was used as an endogenous control. Validation results are expressed as average percent mRNA remaining, relative to Negative Control siRNA-treated samples, along with the standard deviation of multiple independent experiments.